Osteoporosis Management
Introduction to Osteoporosis Treatment
- Osteoporosis treatment guidelines recommend oral bisphosphonates as the first-line pharmacologic treatment due to their favorable balance of benefits, harms, patient values, and cost, according to the American College of Physicians 1
- Bisphosphonates reduce the risk of vertebral and non-vertebral fractures in patients with osteoporosis 1
- Bisphosphonates are the most cost-effective option with generic formulations available 1
Treatment Options
- Zoledronic acid is an excellent option for patients with compliance issues or GI concerns, reducing the risk of hip, vertebral, and non-vertebral fractures, and may be used first-line where there is evidence of malabsorption or increased risk of GI side effects 2, 3, 4
- Risedronate, an oral bisphosphonate alternative to alendronate, reduces the risk of vertebral and non-vertebral fractures and is available in daily, weekly, or monthly dosing formats 4, 5
- Teriparatide, a bone-forming agent, is recommended for patients at very high risk of fracture and significantly improves BMD at lumbar spine and femoral neck 5
- Abaloparatide, a newer anabolic agent, is recommended for patients at very high fracture risk and should be followed by anti-resorptive therapy 5
- The following treatment options are recommended for specific populations:
| Treatment | Recommendation | Population |
|---|---|---|
| Oral Bisphosphonates | First-line treatment | Adults with primary osteoporosis |
| Anabolic Agents | Consider for high fracture risk | Adults ≥40 years with very high fracture risk |
| Denosumab | Consider for patients with contraindications to bisphosphonates | Adults with primary osteoporosis |
| Teriparatide | Conditionally recommended for high fracture risk | Adults ≥40 years with very high fracture risk |
| Zoledronic acid | Recommended for patients with severe osteoporosis and high fracture risk | Adults with severe osteoporosis and high fracture risk [4] |
Dosing Considerations
- In patients with malabsorption, intravenous zoledronic acid may be considered as an alternative to oral bisphosphonates 2
- The American College of Physicians recommends zoledronic acid as the strongest alternative to Prolia and alendronate, administered intravenously at 4 mg every 6 months for 3-5 years, based on high-quality evidence 1, 3
- For patients with renal impairment, use caution with bisphosphonates if eGFR <35 mL/min, and consider dose adjustment or alternative agents, as suggested by the American College of Rheumatology 6
- For patients with malabsorption syndromes, higher doses and more careful monitoring may be required, according to the Autoimmunity Society 7
Special Populations
- Women of childbearing potential should only be considered for bisphosphonate therapy if they are not planning pregnancy during the treatment period and are using effective contraception, as recommended by the American College of Rheumatology 8
- Organ transplant recipients should follow age-related recommendations if their glomerular filtration rate ≥30 ml/min and they have no metabolic bone disease, according to the American College of Rheumatology 9
- HIV-infected patients with vitamin D deficiency, phosphate wasting, or evidence of osteomalacia should be considered for bisphosphonate therapy, as recommended by the Infectious Diseases Society of America 10
Treatment Duration and Monitoring
- Bisphosphonates should be considered for a treatment holiday after 5 years 4
- Anabolic agents are limited to 2 years of treatment per regulatory guidelines 5
- Adherence to anti-resorptive therapy should be assessed using biochemical markers of bone turnover 5
- Vitamin D and calcium repletion should be ensured in all patients 5
- Consider stopping bisphosphonate treatment after 5 years unless strong indication for continuation exists 1
- For patients with normal bone mineral density (BMD), DEXA should be repeated after 2-3 years, and for those with rapid bone loss risk, DEXA should be repeated within 1 year, as recommended by the American Association for the Study of Liver Diseases 11
Discontinuation of Therapy
- When stopping denosumab, it is essential to transition to a bisphosphonate to prevent rebound bone loss and vertebral fractures, as recommended by the American Society of Clinical Oncology 3
- Loss of gained bone mineral density can occur if denosumab is discontinued without replacement therapy, highlighting the importance of a transition plan 3
- Do not abruptly discontinue denosumab without replacement therapy, and administer a bisphosphonate before the next scheduled denosumab dose is due 3
- For most patients, zoledronic acid (4-5 mg IV) is the preferred transition option, which should be administered 5-6 months after the last denosumab injection 3